CAPR

Business Context and Reporting Period

Company: Nile Therapeutics, Inc. (formerly SMI Products, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Nile is a development-stage biopharmaceutical company focused on cardiovascular diseases. Its lead candidate, CD-NP, is a chimeric natriuretic peptide in Phase II clinical studies for acute decompensated heart failure (ADHF). A second candidate, CU-NP, is in pre-clinical development. The company terminated its 2NTX-99 program in January 2009 to focus resources on its natriuretic peptide franchise.

Key Financial Metrics

Debt and Liquidity: The company had no outstanding debt as of December 31, 2008. Current liabilities totaled approximately $1.33 million. Management estimates current resources are sufficient to fund operations through the middle of 2009.

Material Changes vs. Prior Period

• Research and Development (R&D) Expenses: Increased by $4.4 million (85%) to $9.48 million in 2008 compared to $5.12 million in 2007. This increase was driven by $2.7 million in higher clinical development costs (Phase Ib and IIa trials for CD-NP) and $0.9 million in manufacturing expenses. A one-time $0.5 million expense related to the CU-NP licensing agreement was also incurred.
• General and Administrative (G&A) Expenses: Decreased by $0.6 million (12%) to $3.92 million, primarily due to the absence of one-time merger costs and legal fees incurred in 2007.
• Interest Expense: Decreased to negligible levels ($137) in 2008 from $1.09 million in 2007, as convertible notes were converted to equity in September 2007.
• Cash Position: Cash reserves declined significantly from $16.2 million to $5.5 million due to operating losses and no new equity financing in 2008.

Guidance, Outlook, and Risks

Outlook and Guidance:

• CD-NP: Plans to initiate a Phase IIb study in acute heart failure patients in the first half of 2009, with completion expected in 2010.
• CU-NP: Plans to complete pharmacological studies and investigate chronic formulations in 2009.
• 2NTX-99: Program terminated; rights reverted to the licensor.
• Capital Needs: The company expects to require substantial additional capital to fund operations beyond mid-2009. Future funding will likely come from equity or debt offerings, or strategic collaborations.

Risks and Contingencies:

• Going Concern: The filing includes a "substantial doubt" regarding the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
• Regulatory Approval: No products are approved for commercial sale. Success depends on FDA approval, which is uncertain and costly.
• Stock Listing: The company's stock price dropped below the $1.00 minimum required for NASDAQ listing in 2008. While a waiver was obtained until April 19, 2009, there is no guarantee the requirement will be met, risking delisting.
• Intellectual Property: The company relies on licenses from the Mayo Clinic and Dr. Cesare Casagrande. Failure to meet obligations could result in loss of rights.

Key Facts for Investor Verification

• Cash Runway: Verify if the company has secured financing to extend operations beyond the projected mid-2009 date.
• NASDAQ Compliance: Monitor whether the stock price remains above $1.00 to maintain NASDAQ Capital Market listing status.
• Clinical Trial Progress: Confirm the initiation and enrollment rates of the planned Phase IIb study for CD-NP in 2009.
• Impairment Charges: Note the anticipated $48,000 impairment charge in Q1 2009 related to the terminated 2NTX-99 program.
• Dilution Risk: Assess the potential for significant shareholder dilution if the company raises capital through equity offerings.